https://dxm-atlas.org/en/interactions/kratom/
CompareKey points for this combination
A study found no change in DXM metabolism after a single low exposure to kratom [29]. This result applies to the tested conditions; the study did not assess sedation, larger amounts or repeated use.
General concepts in this text
Drug metabolism
Chemical transformation of a medicine in the body.
The resulting substances are metabolites. Transformation can reduce or increase pharmacological activity.
Sources: Drug metabolism
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
Sedation
A drug-induced state of calmness, relaxation or sleepiness.
Sources: Sedation
- NCI Dictionary of Cancer Terms: sedation · Live institutional page read 2026-10-13; separate revision label unavailable
How well is this understood?
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHow do the substances interact?
Can the amount reaching the body change?
ⓘ
CYP3A
A group of related CYP enzymes involved in the chemical transformation of medicines.
CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.
Sources: CYP3A
- Daly: Significance of the minor cytochrome P450 3A isoforms · Clin Pharmacokinet. 2006;45(1):13–31; DOI 10.2165/00003088-200645010-00002; PMID 16430309
- In a study of 12 healthy adults, a single low exposure to kratom tea did not change DXM AUC or Cmax when DXM was used as a CYP2D6 probe. Finding below: Finding [29] · 1
How can the effects add up?
ⓘ
μ-opioid effects and associated respiratory hazards
ⓘ
Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences
What remains unknown?
Under the studied conditions, no significant changes in these DXM pharmacokinetic measures were found. The result concerns a single low exposure to kratom tea. Higher or repeated exposures and concentrates are outside that scope. PHI 3–5 rests principally on extrapolation; the probability of sedation or aspiration remains uncertain [29].
Sources
Check the review’s wording
*A single low exposure did not alter DXM PK; sedation and other exposure conditions remain separate issues [29]
- [29] Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom · Open publication
Evidence and sources
Research publication
[29] · Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom · 2023
Finding [29] · 1
- What was found?
In a study of 12 healthy adults, a single low exposure to kratom tea did not change DXM AUC or Cmax when DXM was used as a CYP2D6 probe.
Finding [29] · 2
- What limits this finding?
Under the studied conditions, no significant changes in these DXM pharmacokinetic measures were found. The result concerns a single low exposure to kratom tea. Higher or repeated exposures and concentrates are outside that scope. PHI 3–5 rests principally on extrapolation; the probability of sedation or aspiration remains uncertain [29].